My Cart [ 0 ]
Home > Antibodies > Research-Grade Biosimilars > Abciximab Biosimilar, Glycoprotein IIb/IIIa Receptor Monoclonal Antibody

Abciximab Biosimilar, Glycoprotein IIb/IIIa Receptor Monoclonal Antibody

Catalog No. Product Name Size List Price (US$) Quantity
C039P Abciximab Biosimilar, Glycoprotein IIb/IIIa Receptor Monoclonal Antibody 1 mg 250.00
C039P Abciximab Biosimilar, Glycoprotein IIb/IIIa Receptor Monoclonal Antibody 5 mg 750.00
C039P Abciximab Biosimilar, Glycoprotein IIb/IIIa Receptor Monoclonal Antibody 20 mg 2000.00
Description

C039P: Abciximab Biosimilar, Glycoprotein IIb/IIIa Receptor Monoclonal Antibody

Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype: Human IgG1 kappa.
Source: The anti-human Glycoprotein IIb/IIIa receptor monoclonal antibody abciximab biosimilar was produced in mammalian cells.
Specificity/Sensitivity: The research grade abciximab biosimilar specifically binds to the human Glycoprotein IIb and IIIa.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by abciximab.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 0.1 EU per 1 ug of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The research grade abciximab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

Background

Abciximab Biosimilar uses the same protein sequences as the therapeutic antibody abciximab.

Abciximab, a glycoprotein IIb/IIIa receptor antagonist, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery. It is a glycoprotein IIb/IIIa inhibitor.

While abciximab has a short plasma half-life, due to its strong affinity for its receptor on the platelets, it may occupy some receptors for weeks. In practice, platelet aggregation gradually returns to normal about 96 to 120 hours after discontinuation of the drug. Abciximab is made from the Fab fragments of an immunoglobulin that targets the glycoprotein IIb/IIIa receptor on the platelet membrane.

Syd Labs also provides the following research grade antibody biosimilar proteins:
Bevacizumab Biosimilar, research grade (VEGF-A)
Ranibizumab Biosimilar, research grade (VEGF-A, Fab produced in E. coli)
Cetuximab Biosimilar, research grade (HER1, ErbB-1, EGFR)
Panitumumab Biosimilar, research grade (HER1, ErbB-1, EGFR)
Trastuzumab Biosimilar, research grade (HER2, ErbB-2, c-neu)
Pertuzumab Biosimilar, research grade (HER2, ErbB-2, c-neu)
Infliximab biosimilar, research grade (TNF alpha)
Adalimumab biosimilar, research grade (TNF alpha)
Rituximab biosimilar, research grade (CD20)
Denosumab biosimilar, research grade (RANKL, RANK ligand, OPGL, TNFSF11, CD254, TRANCE, ODF)
Palivizumab Biosimilar, research grade (RSV)
Omalizumab biosimilar, research grade (IgE)
Eculizumab biosimilar, research grade (C5)

Related Links

See our Privacy Policy